Role of Bruton's tyrosine kinase in B cells and malignancies
S Pal Singh, F Dammeijer, RW Hendriks - Molecular cancer, 2018 - Springer
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
Pathophysiology of chronic graft-versus-host disease and therapeutic targets
Chronic GVHD, an autoimmune disease that follows allogeneic hematopoietic-cell
transplantation, is characterized by infections and debilitating tissue injury leading to …
transplantation, is characterized by infections and debilitating tissue injury leading to …
Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase
Background: Ibrutinib is a Bruton tyrosine kinase inhibitor with remarkable efficacy against B-
cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly …
cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly …
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
Chronic graft-versus-host disease (cGVHD) is a serious complication of allogeneic stem cell
transplantation with few effective options available after failure of corticosteroids. B and T …
transplantation with few effective options available after failure of corticosteroids. B and T …
[HTML][HTML] The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for …
KR Cooke, L Luznik, S Sarantopoulos, FT Hakim… - Biology of Blood and …, 2017 - Elsevier
Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …
and disability in allogeneic hematopoietic cell transplantation recipients and a major …
Ibrutinib treatment improves T cell number and function in CLL patients
M Long, K Beckwith, P Do, BL Mundy… - The Journal of …, 2017 - Am Soc Clin Investig
BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting
Bruton's tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative …
Bruton's tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative …
Current concepts and advances in graft-versus-host disease immunology
Worldwide, each year over 30,000 patients undergo an allogeneic hema-topoietic stem cell
transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency …
transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency …
Chronic graft-versus-host disease: biological insights from preclinical and clinical studies
KPA MacDonald, GR Hill… - Blood, The Journal of the …, 2017 - ashpublications.org
With the increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor–
mobilized peripheral blood stem cell donor grafts and successful treatment of older …
mobilized peripheral blood stem cell donor grafts and successful treatment of older …
Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways
G Chamilos, MS Lionakis… - Clinical Infectious …, 2018 - academic.oup.com
Opportunistic infections caused by Pneumocystis jirovecii, Cryptococcus neoformans, and
ubiquitous airborne filamentous fungi have been recently reported in patients with …
ubiquitous airborne filamentous fungi have been recently reported in patients with …
T cell subsets in graft versus host disease and graft versus tumor
Allogeneic hematopoietic cell transplantation (allo-HCT) is an essential therapeutic modality
for patients with hematological malignancies and other blood disorders. Unfortunately, acute …
for patients with hematological malignancies and other blood disorders. Unfortunately, acute …